Dasatinib 化学構造
分子量: 488.01

高品質保証

文献中の引用(61)

カスタマーフィードバック(10)

Quality Control & MSDS

製品説明

  • Compare Src Inhibitors
    Src製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Dasatinib は、野生型ablとSrcのためのSrc/abl阻害剤で、IC50 がそれぞれ 0.6 nM と 0.8 nMです。
ターゲット Abl Src c-Kit (WT)/c-Kit (D816V)
IC50

0.6 nM

0.8 nM [1]

79 nM/37 nM [2]
In vitro試験 Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
M07ep210 M{XMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLNUXk1PzJiaB?= M4PpUGROW09? MnKxTWM2OD1yLkCwNFA4KM7:TR?= MVmxO|k2PjB6MB?=
K562 M1rVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnPO5k4OiCq NED0VpFFVVOR MX7JR|UxRTBwMECxJO69VQ>? MlTnNVc6PTZyOEC=
M07e NXHF[2Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17OOlczKGh? M{LaUmROW09? NInMSlNKSzVyPUCuNFAyOiEQvF2= NVWxSVNjOTd7NU[wPFA>
ALL3 M1vJcmN6fG:2b4jpZ{BCe3OjeR?= MlzaNE4y|ryP MnjsO|IhcA>? MoPXSG1UVw>? MXLJR|UxRTBwMECwOEDPxE1? MXGxPVg5QTV2MB?=
CML MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofmNlAhdWmw MnflSG1UVw>? M2Lsb2lEPTB;MD6wNFEh|ryP NV3uRYFzOTl{MUmwNVY>
BA/F3 NHnrPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUS3NkBp MnXOSG1UVw>? M1WwO2lEPTB;Nj61PFkh|ryP MlTGNlMxQDh4NES=
BA/F3 NVnFTFVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HnU|czKGh? NIS4PZFFVVOR NGfrcZBKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> MlXBNlMxQDh4NES=
BA/F3 NIjuVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp M{nCVGROW09? M1WwZWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? MorPNlMxQDh4NES=
BA/F3 NVXSOodvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S2RVczKGh? M{nmV2ROW09? M3;3SWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?= MWWyN|A5QDZ2NB?=
BA/F3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor0O|IhcA>? MmnOSG1UVw>? NEm3d41KdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCINEi2V{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAxQc7:TR?= NGrRR24zOzNyMUewNy=>
BA/F3 NYTZOmF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;ndWI4OiCq NFHx[4ZFVVOR NHHiV5FKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NHrTS2YzOzNyMUewNy=>
BA/F3 NVXBTVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS4O|IhcA>? MYjEUXNQ MUHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NIixZWczOzNyMUewNy=>
BA/F3 NHyycHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXG3NkBp MoHUSG1UVw>? MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO NGm0bnEzOzNyMUewNy=>
BA/F3 MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlqzO|IhcA>? M3vPR2ROW09? NWfQTFdPUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= NGTtRokzOzNyMUewNy=>
BA/F3 M4jKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrDO|IhcA>? NWe1bJJVTE2VTx?= MVHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> MYeyN|MxOTdyMx?=
BA/F3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[wS3M3PzJiaB?= M{DBUGROW09? MXPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NETLN5EzOzNyMUewNy=>
BA/F3 NXH0UZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[5elczKGh? NWHCWHpFTE2VTx?= NInPXGVKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? M33GR|I{OzBzN{Cz
BA/F3 NEnqU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fHV|czKGh? M131VGROW09? M3Wyd2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFIvPc7:TR?= M1nCb|I{OzBzN{Cz
T cell NXe3WVVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjPUVY4OiCq M2XqR2ROW09? M3f6T2lvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO NIrMZXEyPzF3NEWxNi=>
WiDr NELOXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL5XYY4OiCq NH\jbllFVVOR NEXUcHVKSzVyPUCuNFUzKM7:TR?= Mli2NVU3OTV3MUK=
PC3 NUm5WoZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\qRmpJPzJiaB?= M{TnfmROW09? NFn6emtKSzVyPUCuNFA6PCEQvF2= M{PBNFE2PjF3NUGy
MDA-MB-231 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorQO|IhcA>? MYDEUXNQ M17o[2lEPTB;MD6wNVIh|ryP NFzodZoyPTZzNUWxNi=>
Hs578T NWX4c4h5S3m2b4TvfIlkKEG|c3H5 NV25UIRpPzJiaB?= NXuwT3ozTE2VTx?= M4HiWGdKPTB;MD6wN{DPxE1? NHnwd|czPDBzNUOyOy=>
HMEC NFvtUldEgXSxdH;4bYMhSXO|YYm= NF7vPWk4OiCq NWLl[3g5TE2VTx?= MXXHTVUxRTFwODFOwG0> NFSzNokzPDBzNUOyOy=>
DU145 M3rNOGN6fG:2b4jpZ{BCe3OjeR?= MlnJO|IhcA>? MnToSG1UVw>? M1e0c2dKPTB;MD6xOkDPxE1? NX;2SZlnOjRyMUWzNlc>
U251 NWq3NVhUS3m2b4TvfIlkKEG|c3H5 Mm\IO|IhcA>? M2PlOGROW09? NUjtZYJYT0l3ME2yMlgyKM7:TR?= NEDDNHgzPDBzNUOyOy=>
NCI60 MW\DfZRwfG:6aXOgRZN{[Xl? M2nQPVczKGh? MkTqSG1UVw>? NUXGVYRyT0l3ME21Mlch|ryP MWeyOFAyPTN{Nx?=
MALME-3M MYXDfZRwfG:6aXOgRZN{[Xl? M2rUOlczKGh? MX3EUXNQ M3XGfWdKPTB;Nj62NUDPxE1? M{PTRVI1ODF3M{K3
KM12 NIKxUZNEgXSxdH;4bYMhSXO|YYm= M3;3S|czKGh? MWrEUXNQ NGL4OnNIUTVyPUeuOFQh|ryP M2fCPVI1ODF3M{K3
SW620 M3LpcGN6fG:2b4jpZ{BCe3OjeR?= NYXRcJZCPzJiaB?= MWrEUXNQ NEjGeFdIUTVyPUiuOFMh|ryP NIPs[oUzPDBzNUOyOy=>
RXF 393NL NVLQOXlJS3m2b4TvfIlkKEG|c3H5 M2XqSFQh\GG7cx?= M{C4dmROW09? M4XvUWlEPTB;MD6wNlE4KM7:TR?= NYS4eYdSOjN{NUOwO|Q>
LXFA 983L MXfDfZRwfG:6aXOgRZN{[Xl? MXm0JIRigXN? NIDydVJFVVOR NFf4TpRKSzVyPUCuNFU3PSEQvF2= NF2wOGwzOzJ3M{C3OC=>
PRXF DU145 M4LUO2N6fG:2b4jpZ{BCe3OjeR?= M37wdVQh\GG7cx?= M2rWSGROW09? MmfLTWM2OD1yLkC2NlMh|ryP MVSyN|I2OzB5NB?=
PAXF 1657L NF3LUWhEgXSxdH;4bYMhSXO|YYm= M{flXFQh\GG7cx?= MmfxSG1UVw>? MlLDTWM2OD1yLkGyNUDPxE1? NIDCVFMzOzJ3M{C3OC=>
CXF 1103L MVzDfZRwfG:6aXOgRZN{[Xl? NELhUoI1KGSjeYO= NGr2dm5FVVOR NXflUoRYUUN3ME20MlM3KM7:TR?= NWm1U3hWOjN{NUOwO|Q>
GXF251L NXOyc4d{S3m2b4TvfIlkKEG|c3H5 M3HBSlQh\GG7cx?= M2K4TmROW09? MkTJTWM2OD1{LkK1JO69VQ>? NWjQTVBPOjN{NUOwO|Q>
NCI-H23 NFHW[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7TO|IhcA>? NYjEXlVCTE2VTx?= MULJR|UxRTJwMkeg{txO M1fwW|I{PTJzMEKw
HCT116 NFjDOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ER4dHPzJiaB?= NVLXUpVPTE2VTx?= NVT5epZ{UUN3ME2yMlMh|ryP M1nMeVI{PTJzMEKw
MCF7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13HZVczKGh? NEjqXm9FVVOR NY\UTFdWUUN3ME2yMlU4KM7:TR?= M3nXOFI{PTJzMEKw
NCI-H460 M{P3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLDXWhkPzJiaB?= M13OSWROW09? M2\WcGlEPTB;OD65PUDPxE1? MYqyN|UzOTB{MB?=
DLD1 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrNO|IhcA>? M1W2[GROW09? MmG0TWM2OD12Lk[g{txO M{jBSlI{PTZ5OU[w
NCI-H661 M3TIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0WFczKGh? NHrsfnRFVVOR NIPBVIRKSzVyPUeuPEDPxE1? MmXWNlM2Pjd7NkC=
A549 NFnCfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFSzPZg4OiCq M3PKOWROW09? MmfhTWM2OD16LkKg{txO Mn3QNlM2Pjd7NkC=
U937 M3n1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\yPJU4OiCq Mk\5SG1UVw>? M{nHdGlEPTB;MUKuNkDPxE1? MlS4NlM2Pjd7NkC=
HEK293 NXHvRWdETnWwY4Tpc44hSXO|YYm= M3m5UFExyqEQvF2= M3TGfWROW09? NWS0SXF2UW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> MVmyNlc4ODZzMB?=
HUVEC NEnBb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHNWYlWOC5zNdMg{txO NG\SPHI4OiCq NI[3b2VFVVOR MYXJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= M13HSFIzQDV|OUmz
HUVEC M4fxemZ2dmO2aX;uJGF{e2G7 Ml[yNVXDqM7:TR?= NVT6[GpyPzJiaB?= NVK5ZXZoTE2VTx?= M{XkOWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZibnX0e49zcyCob4LtZZRqd25iYYSgNU45KHSxIEG1JJVO M1;5PVIzQDV|OUmz
Plasmodium falciparum NV74T|NFTnWwY4Tpc44hSXO|YYm= MnP5NVDDqM7:TR?= NVjOenlsOTVibXnu MXfEUXNQ MkDyTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO NXWzdnJrOjR3NUCzN|A>
PC3 NIX5T2lHfW6ldHnvckBCe3OjeR?= MYCwMlEh|ryP MVy1JIg> NFTCe4hFVVOR M364e2lvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= MU[xPVQ3Ojl5NR?=
DU145 NHjreItHfW6ldHnvckBCe3OjeR?= M4H6flAvOSEQvF2= M2njS|UhcA>? M{DEUmROW09? MkCzTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NVH0[5BMOTl2NkK5O|U>
PC3 NI[yZ4JMcW6jc3WgRZN{[Xl? NV3jTWtYOC5zIN88US=> MV21JIg> M3njZWROW09? MmTSTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= M3nvNFE6PDZ{OUe1
DU145 NHHOW3lMcW6jc3WgRZN{[Xl? M4D5NFAvOSEQvF2= MX61JIg> MWDEUXNQ NIrEfmJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> NFmzfo4yQTR4Mkm3OS=>
PC3 NHfkSHRMcW6jc3WgRZN{[Xl? Mn[wNE4yKM7:TR?= M2T2UVUhcA>? MljxSG1UVw>? NXH2fHUxUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P M1;GXlE6PDZ{OUe1
DU145 MkLiT4lv[XOnIFHzd4F6 M{[2SVAvOSEQvF2= NY\rb4tnPSCq NFW5OWFFVVOR NITVXZdKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= M3nIXlE6PDZ{OUe1
Huh7 MmjkRY51cX[rcnHsJGF{e2G7 M3jGNFIvPSEQvF2= M1W4eVQh\GG7cx?= NI\oc2VFVVOR MVHJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? NF:5O5EyPzN4ME[3Oi=>
C6/36 NXntblR3SW62aY\pdoFtKEG|c3H5 NYTv[GZ7Oi53IN88US=> MV60JIRigXN? NWjWNHRvTE2VTx?= M4nWdGlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MlW3NVc{PjB4N{[=
U937 NWDRcYE5TnWwY4Tpc44hSXO|YYm= MUexJO69VQ>? NVS5OYpNOSCq NYfYfZJnTE2VTx?= M2XrUnJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| M3TIWFE4Pjh2MEm5
U937 NGnJSodHfW6ldHnvckBCe3OjeR?= MknBNUDPxE1? MkD1NUBp MnvxSG1UVw>? MVvS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> M3W0elE4Pjh2MEm5
murine mast cell MlrVSpVv[3Srb36gRZN{[Xl? MVyxJO69VQ>? NITXS28zPCCq NXu0foZZTE2VTx?= M{j1cWlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP MVqxO|Y5PDB7OR?=
BV-173 NVvkS|B2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ryO2lEPTB;MD6wNFAxODBzMEmg{txO M3\0NnNCVkeHUh?=
K-562 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TmOWlEPTB;MD6wNFAxODB{Nk[g{txO Mnn3V2FPT0WU
BL-70 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMECwNFAxQDJ{IN88US=> MXfTRW5ITVJ?
EM-2 NEXxNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Tz[mlEPTB;MD6wNFAxODFyODFOwG0> NHzFfJhUSU6JRWK=
LAMA-84 M1LyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPabFRKSzVyPUCuNFAxODB|MkGg{txO MnXCV2FPT0WU
MEG-01 NXH1fo43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMECwNFA6QCEQvF2= NYnp[YwzW0GQR1XS
EoL-1-cell MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMECwNFE{OSEQvF2= Mk\YV2FPT0WU
CTV-1 NVfiPI5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjObXpKSzVyPUCuNFAxODRyNDFOwG0> MXnTRW5ITVJ?
TE-15 MmfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7RTWM2OD1yLkCwOVg6KM7:TR?= NGewfW1USU6JRWK=
NOS-1 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMEC2NVMh|ryP NXL1SVJxW0GQR1XS
D-336MG NGf5dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS2TWM2OD1yLkCwOlMh|ryP NEjsZXBUSU6JRWK=
LB1047-RCC NVL1XlhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzSemh6UUN3ME2wMlAxQTh7IN88US=> NFnaPWNUSU6JRWK=
LB996-RCC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHjTWM2OD1yLkCwPVkyKM7:TR?= NFTN[IFUSU6JRWK=
SW982 NX3UWIo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEGxNVUh|ryP NETuZ|VUSU6JRWK=
TK10 NUXoV5ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHZPGlKSzVyPUCuNFEyPzRizszN M4nzbXNCVkeHUh?=
A704 NHHvOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEG0PVEh|ryP Mn7HV2FPT0WU
TE-8 NXfQ[Zd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLmWXBKSzVyPUCuNFE2PzZizszN Mne5V2FPT0WU
DOHH-2 M3z5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PTR2lEPTB;MD6wNVcyQSEQvF2= MlnMV2FPT0WU
HOP-62 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHCbplKSzVyPUCuNFE5OzRizszN NUjQOIhUW0GQR1XS
TE-12 NHT2eGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Ue2xKSzVyPUCuNFE5PjFizszN MVLTRW5ITVJ?
KGN NIDGRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfz[Y1KSzVyPUCuNFE6PDJizszN MWfTRW5ITVJ?
NCI-H1648 NHfTdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvHXHd{UUN3ME2wMlAzODFzIN88US=> MlPiV2FPT0WU
OS-RC-2 Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVTWM2OD1yLkCyNFMh|ryP MmjlV2FPT0WU
GB-1 NGXaUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nmR2lEPTB;MD6wNlE2PyEQvF2= MXPTRW5ITVJ?
RXF393 M1nJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETydW5KSzVyPUCuNFI{PTdizszN M4HpbXNCVkeHUh?=
LC-2-ad NI\EfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEK1PFYh|ryP NIK3eGVUSU6JRWK=
KS-1 MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[2NGlEPTB;MD6wNlc{KM7:TR?= MlPtV2FPT0WU
ETK-1 M1HseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LtN2lEPTB;MD6wNlg{OiEQvF2= MoKyV2FPT0WU
SW954 NF;ucWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTMR5htUUN3ME2wMlAzQTJ5IN88US=> NVfQ[XBRW0GQR1XS
Becker NFHRcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHEbWZtUUN3ME2wMlA{ODB|IN88US=> NH[2[ZVUSU6JRWK=
MZ1-PC Mn;ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWniPWJ1UUN3ME2wMlA{OTF7IN88US=> NGHoeXNUSU6JRWK=
ES6 M4fifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T2SmlEPTB;MD6wN|E6OyEQvF2= NF\Nc21USU6JRWK=
KURAMOCHI NWT5dWFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX4VphKSzVyPUCuNFM1QDdizszN M1TyfXNCVkeHUh?=
CGTH-W-1 NIrlNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW1TWM2OD1yLkCzOVQ5KM7:TR?= MVfTRW5ITVJ?
VA-ES-BJ NH3nVY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMEO5NFIh|ryP NVHmflZ7W0GQR1XS
LXF-289 NY\FfoVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSwTWM2OD1yLkCzPVU3KM7:TR?= NHLldWVUSU6JRWK=
MPP-89 M2TCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMESwOFkh|ryP NV3oUFNjW0GQR1XS
SW872 NG[yOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fpRmlEPTB;MD6wOFE3OSEQvF2= MXzTRW5ITVJ?
SNB75 NFHMb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofpTWM2OD1yLkC0OFM2KM7:TR?= M4PBSHNCVkeHUh?=
PSN1 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\3V2lEPTB;MD6wOFQ4PCEQvF2= NFqyc4pUSU6JRWK=
LB831-BLC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\pSIpqUUN3ME2wMlA1PjB7IN88US=> NF7KPGFUSU6JRWK=
MFH-ino MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMES3NlQh|ryP M3uzcnNCVkeHUh?=
TGBC24TKB NHvudYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnHcnpKSzVyPUCuNFQ4PjFizszN NFTDdm5USU6JRWK=
A388 M2HicWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEWwPVUh|ryP M1K0WXNCVkeHUh?=
BB30-HNC M3rkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPRb3RHUUN3ME2wMlA2PDN5IN88US=> MUfTRW5ITVJ?
GI-ME-N MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwME[xNVgh|ryP MkfIV2FPT0WU
TGBC1TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzhTWM2OD1yLkC2NVY1KM7:TR?= MVzTRW5ITVJ?
TE-10 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzyXlhlUUN3ME2wMlA3OzV5IN88US=> M2S3c3NCVkeHUh?=
A498 NWq4UlN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwMEeyPFQh|ryP NVX6[Fd5W0GQR1XS
TE-11 MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTw[VVlUUN3ME2wMlA4QDV6IN88US=> MofFV2FPT0WU
BB65-RCC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMEiyNlch|ryP MXrTRW5ITVJ?
C2BBe1 M4jBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jNWmlEPTB;MD6wPFMxQCEQvF2= MWDTRW5ITVJ?
NCI-H747 M36xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnG[49IUUN3ME2wMlA5OzZ{IN88US=> NEfI[JFUSU6JRWK=
IST-MES1 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXkTWM2OD1yLkC4OVUzKM7:TR?= NHfFPVBUSU6JRWK=
KALS-1 NEmy[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT5c41KSzVyPUCuNFk1QSEQvF2= NET5ZVZUSU6JRWK=
GCIY NUHaOIpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMEm2OVYh|ryP NYrvNHo{W0GQR1XS
RL95-2 NEPUe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMUCzPEDPxE1? MnLUV2FPT0WU
TE-1 NXW0WWJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMUC1OEDPxE1? M1vhRXNCVkeHUh?=
NCI-H1355 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoftTWM2OD1yLkGxNFI5KM7:TR?= NGDvU3RUSU6JRWK=
SW962 NHLtOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMUGyPVIh|ryP MojwV2FPT0WU
KLE NX;Ne21xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT0NY9jUUN3ME2wMlEyOzF5IN88US=> NX[zd3huW0GQR1XS
MC116 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnYSW9KSzVyPUCuNVE1OSEQvF2= MmC2V2FPT0WU
NMC-G1 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHXOohxUUN3ME2wMlEyPjB4IN88US=> MYDTRW5ITVJ?
KU812 M1[wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUG4PFMh|ryP NFnhZ3pUSU6JRWK=
COLO-829 NYLybplpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DBe2lEPTB;MD6xNlIyOyEQvF2= MXHTRW5ITVJ?
NTERA-S-cl-D1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDqT3pKSzVyPUCuNVIzQDNizszN MorZV2FPT0WU
IST-MEL1 NY\QTmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP0NndKSzVyPUCuNVM1PSEQvF2= NVjheo1LW0GQR1XS
MLMA M1vobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jrNGlEPTB;MD6xOFA{OiEQvF2= NEfTPWxUSU6JRWK=
LS-123 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMUSwOlQh|ryP MoS5V2FPT0WU
LB2518-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPpR3lKSzVyPUCuNVQyPjJizszN NV;ybYpuW0GQR1XS
NB69 NI[zWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMUS0N|Yh|ryP NWTGWlIzW0GQR1XS
8-MG-BA M{LCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMUW0OVgh|ryP NX7rPJN1W0GQR1XS
K5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\CdmlEPTB;MD6xOlQ5QSEQvF2= MX;TRW5ITVJ?
KINGS-1 M4XrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKze4dkUUN3ME2wMlE3PjZ4IN88US=> M4GxV3NCVkeHUh?=
SF268 M3S1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXCTWM2OD1yLkG3OFA1KM7:TR?= M3XrcXNCVkeHUh?=
PF-382 NVnFb5dMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fJfGlEPTB;MD6xO|Y4QCEQvF2= M1rjZ3NCVkeHUh?=
SH-4 M2DFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjRZ4VKSzVyPUCuNVg1OTNizszN MXHTRW5ITVJ?
NALM-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGqyOYpKSzVyPUCuNVkzQTVizszN MVrTRW5ITVJ?
CP66-MEL MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjrXplxUUN3ME2wMlE6PTNzIN88US=> NH;ldlZUSU6JRWK=
697 NXzO[ZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn2RohmUUN3ME2wMlE6QTh5IN88US=> NIHhdWhUSU6JRWK=
CP67-MEL Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKyTWM2OD1yLkKwOFg5KM7:TR?= NVLPT|M2W0GQR1XS
DSH1 MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDMPJZKSzVyPUCuNlQxODFizszN NYOzfmx6W0GQR1XS
HCE-4 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMk[0N|kh|ryP M1rVbnNCVkeHUh?=
MZ2-MEL NVvRUZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTNTWM2OD1yLkK4OVM4KM7:TR?= NX;DXVM3W0GQR1XS
BL-41 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMkmxNlMh|ryP NV;oSFZzW0GQR1XS
HUTU-80 MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofyTWM2OD1yLkOxOFIh|ryP MWPTRW5ITVJ?
LOXIMVI M2KzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLLTWM2OD1yLkOxOVA{KM7:TR?= MUTTRW5ITVJ?
no-10 NUfpN2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHOTWdMUUN3ME2wMlMyQTNzIN88US=> NHvGTJdUSU6JRWK=
KARPAS-422 NEHWU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Lxe2lEPTB;MD6zN|k6PyEQvF2= MXfTRW5ITVJ?
SW684 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TicGlEPTB;MD6zOFk5KM7:TR?= NFPQbFVUSU6JRWK=
SF126 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPlRZJKSzVyPUCuN|U1OSEQvF2= M2G2XnNCVkeHUh?=
D-263MG NIr0WFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlT0TWM2OD1yLkO2NlI1KM7:TR?= NXfaWJV5W0GQR1XS
OVCAR-4 M1nzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwM{e0N|Mh|ryP NFnmflRUSU6JRWK=
BB49-HNC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS2fnFyUUN3ME2wMlM5PTl7IN88US=> M2PNNXNCVkeHUh?=
ONS-76 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL0dHdKSzVyPUCuOFI6PTFizszN MX\TRW5ITVJ?
MZ7-mel MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNEe5NVEh|ryP MnjWV2FPT0WU
RCC10RGB MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNEmxNUDPxE1? NFXtbVBUSU6JRWK=
BOKU NEPtOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwcplKSzVyPUCuOFkyOzNizszN MXPTRW5ITVJ?
no-11 NGD6empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHGTWM2OD1yLkWwNlI5KM7:TR?= NVjLOXdNW0GQR1XS
IST-SL2 MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H0[WlEPTB;MD61NFMxOiEQvF2= NGTpeWZUSU6JRWK=
RKO MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLXOIM{UUN3ME2wMlUzQTZ4IN88US=> M2HTZnNCVkeHUh?=
HT-144 M4qz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNUO2NFkh|ryP NHnVdG1USU6JRWK=
NCI-H446 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjXVlZKSzVyPUCuOlI4PiEQvF2= MoD2V2FPT0WU
QIMR-WIL Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjiS|dmUUN3ME2wMlcxPjJ7IN88US=> MUfTRW5ITVJ?
MHH-PREB-1 NFm1RVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LrS2lEPTB;MD63OFQ3QSEQvF2= MY\TRW5ITVJ?
EW-16 M4XQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\hbpdJUUN3ME2wMlc3OTd6IN88US=> NF3JVJRUSU6JRWK=
EW-24 NHL5U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;CVWlEPTB;MD63PFE3PSEQvF2= MWHTRW5ITVJ?
LB373-MEL-D NFv5PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnBe29KSzVyPUCuPFI2ODhizszN MkjjV2FPT0WU
TE-9 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfKUZlKSzVyPUCuPFc2OzJizszN NUTUbXJyW0GQR1XS
A3-KAW NWLie3E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zBO2lEPTB;MD65PFQ2OiEQvF2= MV7TRW5ITVJ?
A101D MknlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkT1TWM2OD1zLkCzNFQ{KM7:TR?= MoXBV2FPT0WU
OCUB-M NID0TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPxeoZKSzVyPUGuNFQ1OTJizszN MXvTRW5ITVJ?
ES4 NF3L[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7zTWM2OD1zLkC1NVQ2KM7:TR?= NGDOcWVUSU6JRWK=
TE-6 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi1d4FKSzVyPUGuNlEzOjZizszN NHTDbZBUSU6JRWK=
D-502MG M4HNe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\mTWM2OD1zLkKzN|c3KM7:TR?= MnewV2FPT0WU
KNS-42 M3ntc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLJTWM2OD1zLkK0OFEzKM7:TR?= MV\TRW5ITVJ?
SNU-C2B NEPyc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;3UGY6UUN3ME2xMlMxPTh7IN88US=> NILBZY9USU6JRWK=
NCI-H1838 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjFbmZLUUN3ME2xMlMxPzN|IN88US=> NXfhRYsyW0GQR1XS
NKM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwM{C4OVkh|ryP NGLOflVUSU6JRWK=
GI-1 NYH3TZU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HSdWlEPTB;MT6zOlIzKM7:TR?= NWj6TYFDW0GQR1XS
NB5 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnCTWM2OD1zLkO5PFI4KM7:TR?= MULTRW5ITVJ?
CAS-1 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILLd3FKSzVyPUGuOFA6QTJizszN M3W1WXNCVkeHUh?=
HCE-T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofyTWM2OD1zLkW2O|E1KM7:TR?= NIrxOWpUSU6JRWK=
SBC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3aT3pKSzVyPUGuOVc6QDRizszN MWHTRW5ITVJ?
JiyoyeP-2003 NFHobmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzCWIhKSzVyPUGuO|M1PjZizszN NYnNUoFoW0GQR1XS
TE-5 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwN{mxN|kh|ryP NHXP[WhUSU6JRWK=
CAN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDKTWM2OD1zLkiyNlUzKM7:TR?= Mk\DV2FPT0WU
SK-UT-1 M{\UbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofPTWM2OD1{LkG2Olk{KM7:TR?= MV\TRW5ITVJ?
JVM-2 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe0UGp2UUN3ME2yMlM3Ojh2IN88US=> MY\TRW5ITVJ?
LB771-HNC NWTXfmFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHmZWJKSzVyPUKuOVc2PTFizszN MUXTRW5ITVJ?
NCCIT MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHUc4tqUUN3ME2yMlg3PjF4IN88US=> NFKzPY5USU6JRWK=
NCI-H2126 MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHIWVN2UUN3ME2yMlg4PTV{IN88US=> MVjTRW5ITVJ?
Calu-6 NVXNSJlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmzW|hKSzVyPUOuNFU4PDFizszN NYfmTIpJW0GQR1XS
SK-LMS-1 NEnsWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoS3TWM2OD1|LkGxPFg3KM7:TR?= MlLtV2FPT0WU
ARH-77 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwNE[5NVUh|ryP NUXxPGpyW0GQR1XS
NB17 NGHoc3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHhRnhPUUN3ME2zMlY{QDR5IN88US=> NFnublRUSU6JRWK=
A253 M3XSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DaWGlEPTB;Mz63N|I1PiEQvF2= MVnTRW5ITVJ?
OPM-2 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[5RlQ5UUN3ME20MlI4Pjh3IN88US=> NUPuOYRuW0GQR1XS
MV-4-11 NGrLfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXMeoZKSzVyPUSuN|Y1PTRizszN M{nIVnNCVkeHUh?=
SR M4KyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPQTWM2OD12LkS5PVU1KM7:TR?= MUHTRW5ITVJ?
KG-1 NH\2[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXYdVhKSzVyPUSuOlA5PDVizszN M3\O[3NCVkeHUh?=
OCI-AML2 M{jvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHKTm9KSzVyPUWuPFYyPTRizszN NFvLT5BUSU6JRWK=
D-247MG M4L6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXflT2ZbUUN3ME22MlEzPTF7IN88US=> NFf2XXBUSU6JRWK=
DJM-1 M{HqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsb3E{UUN3ME22MlQ5PTV6IN88US=> NWG5d29EW0GQR1XS
RPMI-6666 Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLuTWM2OD15LkK3NFY4KM7:TR?= NV\E[3pXW0GQR1XS
KARPAS-45 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzjTWM2OD15LkWxOlcyKM7:TR?= NHzaPJJUSU6JRWK=
LP-1 NUWyRW5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPMZnU2UUN3ME23MlU1Pzh{IN88US=> MoDXV2FPT0WU
RS4-11 NUPqXHc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTdwNkW3PFch|ryP M3q0V3NCVkeHUh?=
DU-4475 MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRThwMkG2OVIh|ryP MV;TRW5ITVJ?
MONO-MAC-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j2VWlEPTB;OD6yO|A3PiEQvF2= Ml23V2FPT0WU
NCI-SNU-16 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonDTWM2OD16LkW2NVI5KM7:TR?= M{PYVXNCVkeHUh?=
SJSA-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRThwN{K4NFUh|ryP MoG0V2FPT0WU
MMAC-SF NV;JbI14T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHKNnZKSzVyPUiuO|k{ODdizszN NUDoUmloW0GQR1XS
SK-NEP-1 NFTtWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HueWlEPTB;OD64PVE2PSEQvF2= Mo\sV2FPT0WU
J-RT3-T3-5 NVfTT2tET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRThwOU[1Nlkh|ryP MVLTRW5ITVJ?
SKM-1 MmC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33EfmlEPTB;OT6wNVc{PCEQvF2= MVTTRW5ITVJ?
LB2241-RCC M2jO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z3O2lEPTB;OT6wNlAyOiEQvF2= MXLTRW5ITVJ?
SIG-M5 NUTGRoNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHl[ZJKSzVyPUmuNFI1QTNizszN NYHPV2lGW0GQR1XS
EVSA-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTlwMke3PVMh|ryP MV7TRW5ITVJ?
GT3TKB MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTlwM{W1OFYh|ryP MUfTRW5ITVJ?
NB6 M4XLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG4bm44UUN3ME25MlkzOjV7IN88US=> MlnmV2FPT0WU
EHEB NGP6TYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;qT4hKSzVyPUGwMlA3PTZizszN M2CzcnNCVkeHUh?=
HEL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jIXmlEPTB;MUCuOFc4PiEQvF2= Mo\4V2FPT0WU
ALL-PO NIiwcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCyTWM2OD1zMD63PVM5KM7:TR?= NYj5W|c3W0GQR1XS
TGW NY\YOZo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPtTWM2OD1zMT6yPFI5KM7:TR?= M{i1fnNCVkeHUh?=
BC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF{LkGxN|gh|ryP MX\TRW5ITVJ?
IA-LM NX;XVVdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n5NGlEPTB;MUKuOFQ1PSEQvF2= NUTiS3l2W0GQR1XS
UACC-257 NGrHcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW5S2Q6UUN3ME2xNk46OTl6IN88US=> NYX0ZlhbW0GQR1XS
KP-N-YS NGOzXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrjTWM2OD1zMj65Nlg{KM7:TR?= MXPTRW5ITVJ?
Raji NV[2RXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPwTWM2OD1zMz63OFk4KM7:TR?= M2fnS3NCVkeHUh?=
SF539 Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:2TJFVUUN3ME2xN{45PTV5IN88US=> MVHTRW5ITVJ?
DMS-153 M1PvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjsOXpKSzVyPUG0MlAxOjhizszN M173XHNCVkeHUh?=
L-540 NFLXU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmyRmpTUUN3ME2xOU4xPjd{IN88US=> MWPTRW5ITVJ?
MN-60 M1:2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnJd2dPUUN3ME2xOU4yQTd7IN88US=> M2XTZnNCVkeHUh?=
RPMI-8866 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\1TZR[UUN3ME2xO{41PDV2IN88US=> MoXFV2FPT0WU
NCI-H510A NFq0[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvFTWM2OD1zOT6zPVc{KM7:TR?= NXX5fIpVW0GQR1XS
NB13 NWLyZ2lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnvdmdKSzVyPUG5MlQ5PzdizszN NFHqUoxUSU6JRWK=
HAL-01 M2ry[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O3cGlEPTB;MUmuO|U1OyEQvF2= NX\BOWFCW0GQR1XS
NCI-H720 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqwWJRKSzVyPUKwMlI4OzNizszN NG[4SmZUSU6JRWK=
REH NETlZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfSS|lKSzVyPUKwMlY{PTdizszN M3jucHNCVkeHUh?=
KNS-81-FD MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ|LkG0OkDPxE1? NHLCcYJUSU6JRWK=
HC-1 NFe4e2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvlOJpKSzVyPUK0MlU2PTFizszN NYmy[WdzW0GQR1XS
NCI-H2141 M3jEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ2Lke3OVQh|ryP NGrIVnlUSU6JRWK=
MOLT-4 NEjhNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXVUmEyUUN3ME2yOk43PzV|IN88US=> Mn30V2FPT0WU
OMC-1 NIL6PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ5LkG0NlIh|ryP MVjTRW5ITVJ?
LC-1F MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHhTWM2OD1{Nz6zNlQ2KM7:TR?= NUXkZnJqW0GQR1XS
NCI-H1304 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DsS2lEPTB;MkiuNVYzQCEQvF2= MlrDV2FPT0WU
BC-1 M4LibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G4dmlEPTB;MkiuOlUyKM7:TR?= MUjTRW5ITVJ?
NCI-H64 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfRXo9KSzVyPUK5MlYzPTNizszN MXXTRW5ITVJ?
MOLT-16 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmzTWM2OD1{OT62NlkzKM7:TR?= MXfTRW5ITVJ?
U-87-MG NFzQSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[4dFhKSzVyPUOwMlc3PiEQvF2= MYPTRW5ITVJ?
GAK MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH4TWM2OD1|MT6yOlg3KM7:TR?= M3\CeHNCVkeHUh?=
ES8 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XDO2lEPTB;M{KuNVI2OiEQvF2= NVu4RpVmW0GQR1XS
HCC1599 NV3pXFdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTQTWM2OD1|Mj6zN|I2KM7:TR?= NFXSOXlUSU6JRWK=
EB-3 NWPTcVN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7XTWM2OD1|ND6zNVE4KM7:TR?= MkTaV2FPT0WU
HCC1187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN3LkiwOVIh|ryP MmHRV2FPT0WU
SK-PN-DW MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXRdHlFUUN3ME2zOk4yQTR|IN88US=> NV\UbFVvW0GQR1XS
JVM-3 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\KeVA3UUN3ME2zO{4zOzN6IN88US=> NGfXR4NUSU6JRWK=
HCC2157 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\CSolKSzVyPUO3Mlk6PDZizszN M3HJR3NCVkeHUh?=
A4-Fuk NXfJOnlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEn6eXBKSzVyPUO4MlExODlizszN MmO2V2FPT0WU
COR-L279 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrRN2hPUUN3ME20NE4zQDVzIN88US=> NInX[2xUSU6JRWK=
DEL MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm[zTWM2OD12MT65NFg3KM7:TR?= NV3Td4R2W0GQR1XS
NCI-H1395 M1GwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1SzWWlEPTB;NEKuNFE3OyEQvF2= NXu5cnI3W0GQR1XS
MHH-NB-11 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrMW|BKSzVyPUSzMlA5OThizszN M1LW[HNCVkeHUh?=
NCI-H2107 NIj6em9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Hr[2lEPTB;NEOuOFg1PiEQvF2= MUDTRW5ITVJ?
NEC8 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXkTWM2OD12ND6zN|Yh|ryP Mn\aV2FPT0WU
COLO-684 MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HEUGlEPTB;NE[uNlI2QCEQvF2= NU\pd5pHW0GQR1XS
LS-411N MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTR6LkS3OFgh|ryP NFTpWZZUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo試験 Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]
臨床試験 Dasatinib has entered in a phase II clinical trial in the treatment of hemangiopericytoma and gastrointestinal stromal tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Kinase autophosphorylation assays Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.

細胞アッセイ:

[1]

細胞株 Ba/F3 cell lines
濃度 ~32 nM
反応時間 72 hours
実験の流れ

Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.

動物実験:

[3]

動物モデル EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
製剤 DMSO
投薬量 30 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Dasatinib SDF
分子量 488.01
化学式

C22H26ClN7O2S

CAS No. 302962-49-8
保管 2年-20℃
6月-80℃in solvent
別名 BMS-354825
溶解度 (25°C) * In vitro DMSO 98 mg/mL (200.81 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% PEG 300/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide

カスタマーフィードバック (10)


Click to enlarge
Rating
Source Cell Res, 2011, 21, 1080-1087. Dasatinib purchased from Selleck
Method Microangiography
Cell Lines embryos
Concentrations 30 μM
Incubation Time
Results MEK1/2 may cooperate with VEGFR to regulate blood vessel lumen diameter. We examined this hypothesis by combining VEGFR inhibitor Sunitinib and MEK1/2 inhibitor U0126. Indeed, U0126 (10 µM) combined with Sunitinib (20 µM) resulted in a reduction of vessel lumen size (Figure F), whereas individually they did not. Combined treatment of another MAP kinase signaling pathway inhibitor Dasatinib (20 µM) with Sunitinib (20 µM) produced a similar phenotype as PP1, whereas each individual inhibitor did not result in any vessel shrinkage even at much higher concentrations ( Figure C).Since there are three major VEGF receptors, it is desirable to determine which receptor is involved in combinatory action with MEK1/2. To address this issue, additional highly selective VEGFR inhibitors PTK787 and ZM323881 were tested. Both of these inhibitors (PTK787 or ZM323881), when individually combined with Dasatinib or U0126, induced a reduction of vessel lumen size (Figure D, E, G, and H).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Assessment of cell viability and apoptosis
Cell Lines B-CLL patient leukemic cells
Concentrations 2-10 μM
Incubation Time 48 h
Results The Dasatinib+Nutlin-3 combination promotes synergistic cytotoxicity in primary CLL cells as well as in p53 wild-type and p53 deleted/ mutated leukemic cell lines.

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Western blot
Cell Lines Leukemic cell lines
Concentrations 10 μM
Incubation Time 24 h
Results Dasatinib marginally affected both the basal levels of p53 and the accumulation of p53 induced by Nutlin-3 in the p53 wild -type cells (Fig. A).Interestingly, however, levels of both MDM2 and p21 proteins, 2 of the best characterized transcriptional targets of p53, weres significantly (P < 0.05) decreased in cells treated with Dasatinib+ Nutlin-3 with respect to cells treated with Nutlin-3 alone (Fig. B).

Click to enlarge
Rating
Source Clin Cancer Res, 2011, 17, 762-770. Dasatinib purchased from Selleck
Method Phospho-kinase array analysis
Cell Lines EHEB cell lines/BJAB cell lines
Concentrations 10 μM
Incubation Time 16 h
Results Although Nutlin-3 had no effects on these pathways, Dasatinib alone as well as Dasatinib+Nutlin-3 markedly inhibited the basal phosphorylation of ERK1/2, p38/MAPK, and Akt . Of interest, the combination of Dasatinib+Nutlin-3 selectively enhanced (P < 0.05) the inhibition of Akt phosphorylation with respect to Dasatinib alone, as validated by Western blot analysis.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method MTT assay
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 1-15 μM
Incubation Time 24-72 h
Results Dasatinib and other TKI decreased the viability of the two myeloid cell lines in a dose- and time-dependent manner. Nevertheless, the anti-leukemic efficacy of Dasatinib and other TKI varied considerably in both cell lines.

Click to enlarge
Rating
Source Biochem Pharmacol , 2011, 82, 1457-1466. Dasatinib purchased from Selleck
Method Evaluation of differentiation
Cell Lines MOLM-13 cells, HL-60 cells
Concentrations 5 μM
Incubation Time
Results In a first series of experiments, we assessed four signs of morphological differentiation, May-Gruenwald-Giemsa staining of MOLM-13 cells demonstrated that dasatinib induced a dose-dependent decrease in cytoplasmic basophilia and in the nucleo-cytoplasmic ratio. Dasatinib also led to the appearance of dented nuclei and cytoplasmic granulation( Fig.A and B).In HL-60 cells,dasatinib(5 μM) once more exhibited the highest differentiation-inducing capacity. Thus dasatinib diminished basophilia of the cytoplasm concomitantly with the nucleo-cytoplasmic ratio, and induced the appearance of nuclear lobulation and cytoplasmic granules(Fig. G). Next, we determined the degree of CD11b expression, a marker indicating myeloid differentiation, in TKI-treated MOLM-13 dasatinib exhibited the most pronounced capacity to increase CD11b surface expression( Fig. C and D).To corroborate the TKI-driven differentiation, we quantified the enzymatic activity of alkaline phosphatase by means of the NBT-reduction assay after an incubation period of 6 days in MOLM-13 cells.,Once again, the NBT-reductive activity was highest in cells treated with dasatinib, which was as active as the positive control, ATRA( Fig. E and F)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Assessment of cell viability
Cell Lines leukemic cells
Concentrations 10 μM
Incubation Time 24/48 h
Results Dasatinib dose-dependently reduced cell viability in all leukemic cell lines, with variable efficacy irrespect ively of the p53 status. In particular, when used at 10 μM, Dasatinib induced a progressive decrease of the total number of viable cells ranging from approximately 30% (JVM-2 and MEC-2) to 50% (EHEB and BJAB) after 48 h of treat ment (Fig.a). In order to investigate whet her the decreased leukemic cell viability was mainly due to either cytotoxic or cytostatic activity, we have analyzed the effects of Dasatinib on apoptosis,As shown in Fig. b, exposure to Dasatinib induced a significant (p < 0.05) increase of apoptosis in all leukemic cell lines, as evaluated by Annexin-V/PI staining at 48 h of treatment.

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method phospho-kinase array analysis
Cell Lines EHEB (p53wt) cell lines, BJAB (p53mut) B cell lines
Concentrations
Incubation Time 24 h
Results As shown in Fig. a , the most evident effects of Dasatinib in both cell models were represented by a significant down-regulation of the phosphorylation levels of p38 MAPK, ERK1/2 and CREB. In addition, densitometric analysis of the phospho-kinase array demonstrated that Dasatinib also inhibited the phosphorylation levels of several STAT family members (STAT1, STAT2, STAT3, STAT5a/b and STAT6), the most evident effect in both p53 wild-type (EHEB) and p53 mutated (BJAB) cell lines being on STAT2, STAT3 and STAT6 (Fig. b)

Click to enlarge
Rating
Source Invest New Drugs , 2010, 30, 417-422. Dasatinib purchased from Selleck
Method Western blot
Cell Lines p53wild-type(EHEB, JVM-2) cell lines, p53mutated(MEC-2, BJAB) cell lines
Concentrations 10 μM
Incubation Time 24 h
Results "Upon exposure to Dasatinib, a decrease of phosphorylated proteins was confirmed by Western blot analys is in all cell lines investigated without significant differences between p53wild-type and p53mutated cell lines.

Click to enlarge
Rating
Source Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck
Method Cell vability assays
Cell Lines A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2, HepG2 cell lines
Concentrations 0.001-1000 nM
Incubation Time 24/96 h
Results

文献中の引用 (61)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Src 阻害剤

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Defactinib (VS-6063, PF-04554878)

    Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.

  • Saracatinib (AZD0530)

    Saracatinib(AZD0530)は、c-SrcのためのSrc阻害剤で、IC50 が2.7 nMです。

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Bosutinib (SKI-606)

    Bosutinib(SKI-606)はそれぞれ1.2nMと1nMのIC50値による新しい二重Sarcoma/アベルソン(Src/Abl)チロシン・キナーゼ阻害剤です。

  • KX2-391

    KX2-391は、Srcのサブストレート結合部位を目標とする非常に選択的な非ATP Srcキナーゼ阻害剤で、Srcの高水準を表すガン細胞線で、非常に強い反増殖的な活性を示します。

  • PP1

    PP1は、Lck/Fynのための強力で選択的なSrc阻害剤で、IC50 が 5 nM/ 6 nMです。

  • PP2

    PP2は、Src キナーゼ阻害剤で、GST-Src活動を強力に禁止します。

最近チェックしたアイテム

Tags: Dasatinibを買う | Dasatinib供給者 | Dasatinibを購入する | Dasatinib費用 | Dasatinib生産者 | オーダーDasatinib | Dasatinib代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ